QNCX

Quince is a pre-revenue clinical-stage biopharma in acute financial distress, and the filing language confirms the numbers rather than softening them. Management's MD&A explicitly flags 'our ability to continue as a going concern' and frames the strategy around 'pursuing strategic alternatives, such as completing a reverse merger or selling assets' — the vocabulary of a company preparing for an endgame, not a growth story. Everything else in the data corroborates that: with only $5.81M of cash against $41.4M of operating cash burn in FY2025, the company holds well under two months of runway, while $18.0M of debt (current portion) comes due and the EIB Loan carries covenants that even prohibit dividends. Current assets of $22.9M against current liabilities of $43.2M (up 494% YoY) leave negative working capital.

The balance sheet is already insolvent on a book basis: stockholders' equity is -$35.7M (down 218% YoY) as total liabilities jumped 53% to $129M while total assets shrank 18% to $93.5M, giving a nonsensical -3.62x liabilities/equity. Accumulated deficit sits at -$460M. There is no revenue line in any year 2021-2025, so there is no fundamental engine to grow into the balance sheet — R&D rose 90% to $35.4M even as net loss widened to -$84.0M (from -$56.8M), meaning spending accelerated into a cash wall. Shares outstanding ballooned 270% to 163M, so existing holders have already been heavily diluted, and any survival financing from this cash position would dilute them further, likely at distressed terms.